Tideglusib is under the investigation for the development of treatments for Alzheimer's disease and for progressive supranuclear palsy. It is reported to be a potent anti-inflammatory and neuroprotective that is... It is reported to be a potent anti-inflammatory and neuroprotective that is a non-ATP competitive inhibitor of glycogen synthase kinase 3 (GSK-3).
- Mechanism
- Curator reviewed · 2 references
GSK-3 is a proline/serine protein kinase that is ubiquitously expressed and involved in many cellular signaling pathways. From all its diverse functions, it plays a key role in Alzheimer's disease. This role is related to its link with β-amyloid and tau pathology. It has been suggested that aberrant Wnt or insulin signaling results in increased GSK-3 function. This kinase acts on γ-secretase producing the hyperphosphorylation of tau, the formation of neurofibrillary tangles and senile plaques. Tideglusib inhibits GSK-3 irreversibly by presenting a non-competitive inhibition pattern with respect to ATP. The binding of tideglusib seems to directly relate to the motif containing Cys199.
- Primary indication
- Tideglusib was initially formulated for the treatment of Alzheimer and progressive supranuclear palsy.Curator reviewed
- Formula / weight
- C19H14N2O2S · 334.39 g/mol (avg)
- Also known as
- 4-BENZYL-2-(A-NAPHTYL)-1,2,4-THIADIAZOLIDINE-3,5-DIONE
- Code names
- NP-031112 · NP-12
Resolves to
PMJIHLSCWIDGMD-UHFFFAOYSA-NSMILESO=C1SN(C(=O)N1CC1=CC=CC=C1)C1=C2C=CC=CC2=CC=C1What you can answer from here — as of April 23, 2025
Which drugs share a target with Tideglusib, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account